FindTrial
Sign In

Mechanistic Function of Mitochondrial Carrier Homolog 2 (MTCH2) in Castration-Resistant Prostate Cancer (CRPC) and Its Potential as a Tumor Biomarker

Mechanistic Function of Mitochondrial Carrier Homolog 2 (MTCH2) in Castration-Resistant Prostate Cancer (CRPC) and Its Potential as a Tumor Biomarker

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102981
Enrollment
Unknown
Registered
2025-05-22
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer

Interventions

Tumor group:None
Control group:None

Sponsors

Affiliated Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically clear diagnosis of prostate cancer; 2. Patients undergoing radical prostatectomy surgery; 3. Paraffin-embedded tissue specimens after surgery are kept in the pathology department; 4. Complete clinical and pathological data.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years old or older than 85 years old; 2. Patients with tumors other than prostate cancer; 3. Incomplete surgical specimens or clinical information in other hospitals; 4. Patients with insufficient surgical specimens for immunohistochemistry again.

Design outcomes

Primary

MeasureTime frame
Mitochondrial Carrier Homolog 2;Sterol Regulatory Element Binding Transcription Factor 1;Sterol Regulatory Element Binding Transcription Factor 2;—

Countries

China

Contacts

Public ContactYankui Liu

Affiliated Hospital of Jiangnan University

lykyoung@qq.com+86 510 68089285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026